



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/473694/2015

European Medicines Agency decision P/0168/2015

of 7 August 2015

on the granting of a product specific waiver for brentuximab vedotin (Adcetris), (EMA-000980-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0168/2015

of 7 August 2015

on the granting of a product specific waiver for brentuximab vedotin (Adcetris), (EMA-000980-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Takeda Pharma A/S on 16 March 2015 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 June 2015 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A waiver for brentuximab vedotin (Adcetris), powder for concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Takeda Pharma A/S, Dybendal Alle 10, 2630 - 2630 Taastrup, Denmark.

Done at London, 7 August 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/393132/2015

London, 19 June 2015

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-000980-PIP02-15

Scope of the application

Active substance(s):

Brentuximab vedotin

Invented name:

Adcetris

Condition(s):

Treatment of Cutaneous T-Cell Lymphoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Takeda Pharma A/S

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Takeda Pharma A/S submitted to the European Medicines Agency on 16 March 2015 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 21 April 2015.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition

Treatment of cutaneous T-cell lymphoma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- for powder for concentrate for solution for infusion, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Treatment of Hodgkin lymphoma

Authorised indication(s):

- Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):
 - following autologous stem cell transplant (ASCT) or
 - following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

2. Treatment of anaplastic large cell lymphoma

- Adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)

Authorised pharmaceutical form(s)

Powder for concentrate for solution for infusion

Authorised route(s) of administration

Intravenous use